GlassScriptPhysician profile
Daniel P Welch
NPI 1497396394
$8,392.97
in general payments reported to CMS, 2019-2025
60 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,998 · 2022: $3,182 · 2023: $2,547 · 2024: $404 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553 · Education: $377 · Long Term Medical Supply Or Device Loan: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.71 |
| Education | $376.98 |
| Long Term Medical Supply Or Device Loan | $282.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,275.16 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $487.91 | 2021-2025 | Keytruda, Lynparza |
| Amgen INC. | $480.27 | 2021-2022 | |
| Janssen Biotech, INC. | $445.72 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $443.04 | 2021-2024 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $405.75 | 2021-2025 | Imfinzi, Tagrisso, Lynparza |
| Seagen INC. | $317.45 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Celgene Corporation | $284.73 | 2022-2024 | Reblozyl |
| Daiichi Sankyo INC. | $251.53 | 2021-2024 | Enhertu |
| Genentech USA, INC. | $226.18 | 2022-2025 | Polivy, Venclexta |
| Eisai INC. | $213.25 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $210.09 | 2021-2023 | |
| Genzyme Corporation | $209.04 | 2021-2023 | |
| Pfizer INC. | $193.80 | 2021-2023 | |
| Lilly USA, LLC | $159.47 | 2021-2023 | Jaypirca |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.